2-Deoxy-D-glucose

Drug Profile

2-Deoxy-D-glucose

Alternative Names: 2-Deoxyglucose; 2-DG

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Threshold Pharmaceuticals
  • Developer NeuroGenomeX; Threshold Pharmaceuticals; University of Wisconsin-Madison
  • Class Antineoplastics; Deoxy sugars
  • Mechanism of Action Antimetabolites; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain injuries; Epilepsy
  • Discontinued Solid tumours

Most Recent Events

  • 20 Jul 2016 Preclinical development is ongoing in Epilepsy and Brain injuries
  • 22 Apr 2009 Pharmacodynamics data from a preclinical study in Cancer presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 01 May 2006 Data presented at the 97th Annual Meeting of the American Association for Cancer Research (AACR-2006) have been added to the pharmacokinetics and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top